Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
JAK3 Inhibitor
JAK3-IN-19 is a selective inhibitor of Janus kinase 3 (JAK3), a critical component in cytokine signaling pathways. Inhibition of JAK3 has been shown to affect the proliferation and survival of cancer cells. This compound is valuable for research applications focused on understanding the role of JAK3 in various malignancies and exploring its potential as a therapeutic target in cancer treatment. -
JAK Inhibitor
(3S,4R)-Tofacitinib is a less active enantiomer of Tofacitinib, primarily targeting Janus kinase 3 (JAK3) as a potent inhibitor. It exhibits an IC50 of 1 nM, highlighting its potential for modulating immune responses and inflammatory processes. This compound is valuable for research in immunology and the development of therapies targeting JAK-mediated signaling pathways. -
JAK Inhibitor
AS2553627 is a selective JAK inhibitor, exhibiting IC50 values of 0.46 nM for JAK1, 0.30 nM for JAK2, 0.14 nM for JAK3, and 2.0 nM for TYK2. This compound effectively inhibits the proliferation of human and rat T cells in response to IL-2, with IC50 values of 2.4 nM and 4.3 nM, respectively. In preclinical studies, AS2553627 has demonstrated a capacity to mitigate cardiac allograft vasculopathy and fibrosis in rat heart transplant models, thereby improving survival rates and showing potential for use in preventing acute and chronic rejection in heart transplantation. -
JAKs Inhibitor
JAK-IN-34 is a potent inhibitor of Janus kinases (JAKs), demonstrating low nanomolar IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3, and 1.95 nM for TYK2. This compound effectively reduces joint swelling, indicating its potential application in inflammatory diseases and autoimmune disorders. Its favorable safety profile makes it a valuable tool for research focused on JAK signaling pathways and related therapeutic interventions. -
JAK Inhibitor
JAK3-IN-7 is a potent and selective inhibitor of Janus kinase 3 (JAK3) with an IC50 of less than 0.01 μM. This compound effectively modulates JAK3-mediated signaling pathways, which are critical for immune response and hematopoiesis. JAK3-IN-7 is valuable for research applications focused on autoimmune diseases, inflammatory disorders, and hematological malignancies. -
CK2/PIM1 Inhibitor
CK2/PIM1-IN-1 is a selective inhibitor targeting casein kinase 2 (CK2) and PIM1, demonstrating IC50 values of 3.787 μM and 4.327 μM, respectively. This compound is designed for research into proliferative disorders, particularly cancer, and has potential applications in studying kinase-related conditions such as inflammation, pain, vascular disorders, pathogenic infections, and certain immunological disorders. -
STAT6 Inhibitor
STAT6-IN-7 is a potent inhibitor of STAT6, effectively disrupting the binding of human STAT6 to phosphorylated IL-4 receptor alpha (pIL-4Rα) with an IC50 value of 0.28 μM. Its mechanism of action makes it a valuable tool in the study of inflammatory and allergic diseases, aiding researchers in elucidating the role of STAT6 in these pathological conditions. -
STAT6 Inhibitor
STAT6-IN-9 is a selective inhibitor of Signal Transducer and Activator of Transcription 6 (STAT6), demonstrating an EC50 value of 4 nM. This compound effectively interferes with STAT6 activation driven by the IL-13-IL-13 receptor/IL-4 receptor signaling pathway. Additionally, STAT6-IN-9 inhibits CCL17 secretion with an IC50 of 4.6 nM. It is a valuable tool for investigating chronic inflammatory diseases associated with STAT6 dysregulation, including allergies, asthma, and chronic obstructive pulmonary disease. -
STAT6 Inhibitor
STAT6-IN-10 is a potent inhibitor of signal transducer and activator of transcription 6 (STAT6), exhibiting an EC50 of 0.002 μM. This compound effectively inhibits the secretion of CCL17 in peripheral human whole blood with an IC50 of 0.095 μM, making it a valuable tool for studying inflammatory responses. STAT6-IN-10 is applicable in research focused on dermatological and respiratory conditions, providing insights into therapeutic interventions targeting these pathways. -
STAT6 Inhibitor
STAT6-IN-3 is a potent STAT6 inhibitor designed to selectively target the SH2 domain of STAT6, exhibiting a high binding affinity with an IC50 value of 0.04 μM. This compound is valuable in studying inflammatory processes, particularly in disorders such as asthma, by providing insights into the modulation of STAT6 signaling pathways. Researchers can utilize STAT6-IN-3 to explore its effects on cytokine signaling and immune response regulation. -
STAT3 Inhibitor
SI-109 is a potent inhibitor of the STAT3 SH2 domain, demonstrating an inhibitory constant (Ki) of 9 nM. This compound effectively reduces the transcriptional activity of STAT3 with an IC50 value of 3 μM. SI-109 is utilized in research applications involving antitumor activity and has been instrumental in the development of PROTAC STAT3 degrader SD-36, an important tool in targeted protein degradation studies. -
STAT6 Inhibitor
YM-341619 is a potent STAT6 inhibitor with an IC50 of 0.70 nM, demonstrating effective modulation of Th2 cell differentiation in mouse spleen T cells induced by IL-4, with an IC50 of 0.28 nM. This compound selectively inhibits Th2 differentiation without impacting Th1 cells, making it a valuable tool for research into allergic diseases, including allergic asthma. Its oral bioavailability enhances its utility in in vivo studies aimed at understanding the role of STAT6 signaling in immune responses. -
STAT6 Inhibitor
STAT6-IN-1 is a potent STAT6 inhibitor that specifically targets the SH2 domain of STAT6 with an IC50 value of 0.028 µM. This compound demonstrates significant biological activity in the modulation of signaling pathways associated with allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease, and various cancer types. STAT6-IN-1 is a valuable tool in research applications focused on elucidating the role of STAT6 in inflammatory and oncogenic processes. -
STAT6 Inhibitor
AS1810722 is a potent inhibitor of STAT6, exhibiting an IC50 of 1.9 nM. This compound possesses a favorable profile regarding CYP3A4 inhibition. As a derivative of fused bicyclic pyrimidine, AS1810722 is poised for research applications in allergic diseases, including asthma and atopic disorders. -
STAT6 Inhibitor
STAT6-IN-4 is a selective inhibitor of Signal Transducer and Activator of Transcription 6 (STAT6), exhibiting an IC50 value of 0.34 μM. This compound has significant potential in the study of inflammatory and allergic conditions, providing researchers the ability to investigate the roles of STAT6 in disease pathogenesis and therapeutic responses. Its application can aid in elucidating the molecular mechanisms underlying STAT6-mediated pathways. -
STAT6 Inhibitor
STAT6-IN-5 is a selective inhibitor of STAT6, demonstrating an IC50 value of 0.24 μM. This compound is primarily utilized in the investigation of inflammatory and allergic diseases, such as atopic dermatitis. Its efficacy in modulating STAT6 activity makes it a valuable tool for exploring therapeutic strategies in related biological pathways. -
STAT6 Inhibitor
STAT6-IN-2 is a selective inhibitor of STAT6, effectively blocking the tyrosine phosphorylation of this transcription factor. By inhibiting STAT6, it reduces the secretion of eotaxin-3, which is pivotal in the inflammatory response. This reagent is particularly valuable for research into immune diseases and allergic inflammatory conditions, including asthma, providing insights into the underlying mechanisms and potential therapeutic targets. -
STAT6 Inhibitor
PM-43I is a potent inhibitor of Signal Transducer and Activator of Transcription 6 (STAT6), effectively reducing its phosphorylation levels. This compound demonstrates significant biological activity in the modulation of immune responses and inflammatory pathways. PM-43I is applicable in research related to allergic lung diseases, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and cancer, making it a valuable tool for investigating STAT6-mediated mechanisms. -
STAT3 Inhibitor
LLL12 is a potent inhibitor of STAT3, specifically targeting its phosphorylation. By interfering with the STAT3 signaling pathway, LLL12 demonstrates significant anti-tumor activity, particularly enhancing the effects of Cisplatin and Paclitaxel on ovarian cancer cell proliferation, migration, and growth. This compound is valuable for research in cancer biology and therapeutic development, especially in exploring combinatorial treatment strategies. -
STAT5a Inhibitor
Stafia-1 is a selective inhibitor of STAT5a, exhibiting a Ki of 10.9 μM and an IC50 of 22.2 μM. It demonstrates significant selectivity for STAT5a over STAT5b and other members of the STAT family. This compound is valuable for research investigating the role of STAT5a in cellular signaling pathways and its implications in various diseases, including cancer and inflammation. -
STAT3 Dimerization Inhibitor
STX-0119 is a selective inhibitor of STAT3 dimerization, targeting the STAT3 signaling pathway. By inhibiting STAT3 transcription with an IC50 of 74 μM, STX-0119 effectively disrupts the aberrant activation of STAT3, which is implicated in various cancers and inflammatory diseases. This compound is valuable for research applications focused on understanding the role of STAT3 in tumorigenesis and potential therapeutic interventions. -
STAT3 Inhibitor
STAT3-IN-25 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). It exhibits significant inhibition of STAT3 luciferase activity in HEK293T cells, displaying an IC50 of 22.3 nM, and inhibits ATP production in BxPC-3 pancreatic cancer cells with an IC50 of 32.5 nM. This compound shows potential for use in research focused on pancreatic cancer and other conditions linked to aberrant STAT3 signaling. -
STAT5b SH2 Inhibitor
Stafib-1 is a selective inhibitor of the STAT5b SH2 domain, exhibiting a Ki value of 44 nM and an IC50 of 154 nM. It effectively disrupts STAT5b signaling, which plays a crucial role in various cellular processes, including proliferation and apoptosis. Stafib-1 is valuable for research applications aimed at understanding oncogenic signaling pathways and exploring potential therapeutic strategies for STAT5b-driven malignancies. -
STAT5b Inhibitor
Stafib-2 is a selective inhibitor of the transcription factor STAT5b, demonstrating an IC50 of 82 nM specifically for STAT5b and 1.7 μM for STAT5a. This compound is critical for studies exploring the role of STAT5b in various biological processes, including cell proliferation and survival. Although Stafib-2 exhibits limited cell permeability, it remains a valuable tool for researchers investigating signaling pathways associated with STAT5b in cancer and other diseases. -
STAT3 Inhibitor
5-FAM-GpYLPQTV-NH2 is a fluorescently labeled peptide that inhibits the signal transducer and activator of transcription 3 (STAT3). This compound exhibits significant biological activity as a STAT3 inhibitor, making it a valuable tool for cancer research. Its fluorescent properties enable easy tracking in various biological assays, facilitating the study of STAT3-mediated pathways in tumor biology. -
STAT5 Inhibitor
HODHBt is a STAT5 inhibitor that disrupts the interaction between STAT5 and SUMO, thereby preventing the SUMOylation of phosphorylated STAT5. This action enhances IL-15 signaling, which significantly improves the cytotoxicity and functionality of natural killer (NK) cells, as well as promotes the generation of cytokine-induced memory-like (CIML) NK cells. HODHBt is valuable for research into HIV infection and cancer therapies. -
STAT6 Inhibitor
PM-81I is a potent inhibitor of STAT6, targeting its SH2 structural domain to effectively reduce STAT6 phosphorylation levels. This compound serves as a valuable tool in research related to allergic lung diseases, allergic rhinitis, chronic obstructive pulmonary disease, and various cancer studies. Its ability to modulate STAT6 activity makes it relevant for elucidating the molecular mechanisms underlying these conditions. -
STAT3 Inhibitor
STAT3-IN-17 is a selective inhibitor of the signal transducer and activator of transcription 3 (STAT3), exhibiting an IC50 of 0.7 μM in HEK-Blue IL-6 assays. This compound demonstrates antiproliferative effects in HeLa cancer cell lines, making it valuable for oncology research. Additionally, STAT3-IN-17 inhibits pyruvate-ferredoxin oxidoreductase (PFOR) and has shown efficacy against Helicobacter pylori, further expanding its potential applications in microbiological studies. -
STAT3 Inhibitor
MM-206 is a potent inhibitor of the STAT3 SH2 domain-phosphopeptide interaction, with an IC50 of 1.2 μM. This compound induces apoptosis in a dose-dependent manner in acute myeloid leukemia (AML) cell lines. MM-206 is valuable for research applications focused on understanding the role of STAT3 in cancer biology and exploring potential therapeutic strategies targeting this pathway. -
STAT3 Inhibitor
STAT3-IN-20 is a selective inhibitor of the STAT3 protein, exhibiting an IC50 value of 0.65 μM. By binding to the SH2 domain, this compound effectively inhibits STAT3 phosphorylation, translocation, and subsequent downstream gene transcription. Demonstrating significant antiproliferative activity, STAT3-IN-20 shows IC50 values of 2.97 μM against STAT3-overactivated DU145 cells and 3.26 μM against MDA-MB-231 cancer cells. Furthermore, STAT3-IN-20 induces cell cycle arrest and apoptosis, making it a valuable tool for research in cancer therapeutics targeting the STAT3 signaling pathway. -
STAT3 Inhibitor
STAT3-IN-14 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), demonstrating potent inhibitory activity against STAT3 phosphorylation. By binding directly to the hinge region of STAT3, this compound effectively disrupts its activity, making it a valuable tool for research applications targeting STAT3-mediated signaling pathways. It is useful in studies of cancer, inflammation, and autoimmune diseases where STAT3 plays a critical role in disease progression. -
CXCR4/STAT3 Inhibitor
Minecoside is a potent inhibitor of the CXCR4 receptor and STAT3 signaling pathway. It demonstrates significant anticancer and anti-inflammatory activities by downregulating CXCR4 expression and suppressing STAT3 activation, which leads to the inhibition of CXCL12-induced cellular invasion. Minecoside has been shown to effectively hinder cancer metastasis and enhance apoptosis, making it a valuable tool for research in cancer biology and therapeutic development. -
STAT3 inhibitor
(+)-Ochromycinone is a natural antibiotic that serves as a potent inhibitor of STAT3. Its primary biological activity is the modulation of signaling pathways involved in cancer progression and inflammatory responses. This compound is widely utilized in research applications focusing on cancer biology and dermatological diseases such as psoriasis. -
STAT3 Inhibitor
Galiellalactone is a selective inhibitor of STAT3 signaling, exhibiting an IC50 value of 250-500 nM. This small, non-toxic, and non-mutagenic fungal metabolite is relevant for research involving castration-resistant prostate cancer, providing insights into the mechanisms of cancer biology and therapeutic resistance. Its specificity towards STAT3 makes it a valuable tool for studying the role of this pathway in various cellular processes. -
STAT3 Inhibitor
MC0704 is a selective STAT3 inhibitor with an IC50 of 2.13 μM. This compound effectively induces apoptosis and triggers cell cycle arrest, demonstrating significant antitumor activity in murine models of breast cancer. MC0704 is a valuable tool for investigating therapeutic strategies in metastatic triple-negative breast cancer (mTNBC) research. -
STAT3 Inhibitor
STAT3-IN-24 is a cell-permeable inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3). This peptide inhibitor effectively disrupts the recruitment of STAT3 to Janus Kinase 2 (Jak2) and inhibits the phosphorylation of tyrosine 705, thereby preventing STAT3 dimerization and its subsequent nuclear translocation. STAT3-IN-24 is applicable in studies investigating the oncogenic role of STAT3 and its potential as a therapeutic target in various malignancies. -
STAT Inhibitor
JI069 is a selective JAK-STAT inhibitor that effectively targets the STAT signaling pathway. It demonstrates potent inhibition of STAT3, as well as other STAT proteins including STAT1, STAT5, and STAT6, thereby suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. Due to its ability to inhibit cytokine production from T cells and decrease STAT3 phosphorylation in synovial cells, JI069 exhibits significant therapeutic potential in models of collagen-induced arthritis. -
STAT3 Inhibitor
Eucannabinolide is a STAT3 inhibitor that targets the activation of STAT3 at tyrosine 705, inhibiting its translocation to the nucleus and reducing its DNA binding capacity. This compound demonstrates potential in studies related to triple-negative breast cancer (TNBC) and other diseases characterized by aberrant STAT3 signaling. Eucannabinolide serves as a valuable tool for researchers investigating therapeutic strategies aimed at modulating STAT3 pathways in oncogenesis. -
STAT3 Inhibitor
STAT3-IN-37 is a selective inhibitor of the transcription factor STAT3, exhibiting potent inhibitory activity with an IC50 of 15 nM in a DNA-HTRF assay and 2 nM in a human whole blood assay utilizing SOCS3 qPCR. This compound is valuable for research applications targeting STAT3-mediated signaling pathways, often implicated in oncogenesis and immune regulation. Its efficacy makes it a suitable tool for studies investigating the therapeutic potential of STAT3 modulation in cancer and inflammatory diseases. -
Hsp110-STAT3 Interaction Inhibitor
Hsp110-STAT3 PPI-IN-1 is a potent inhibitor of the Hsp110-STAT3 protein-protein interaction. This compound exhibits antiproliferative activity against the HPAEC cell line, demonstrating an IC50 value of 22.67 μM. It serves as a valuable tool for investigating the role of Hsp110-STAT3 interactions in various biological processes and therapeutic applications. -
STAT3 Inhibitor
S3I-1757 is a selective STAT3 inhibitor that effectively hinders the phosphorylation and dimerization of STAT3 proteins. By targeting this pathway, S3I-1757 demonstrates significant potential in the study of STAT3-driven malignancies, including melanoma. Its application is particularly relevant for investigating therapeutic strategies in cancers characterized by aberrant STAT3 activation. -
STAT3 Inhibitor
Ac-GpYLPQTV-NH2 is a selective inhibitor of the STAT3 signaling pathway, exhibiting an IC50 value of 0.33 μM. This compound demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutic applications targeting STAT3-mediated oncogenic functions. Its efficacy in modulating STAT3 activity provides insights into the role of this transcription factor in tumor progression and treatment resistance. -
STAT5a Inhibitor
Stafia-1-dipivaloyloxymethyl ester functions as a selective inhibitor of STAT5a. This compound effectively reduces the expression of phosphorylated STAT5a (pSTAT5a) in a concentration-dependent manner, demonstrating significant inhibition at doses ranging from 0-200 μM, while exhibiting minimal impact on phosphorylated STAT5b (pSTAT5b). Stafia-1-dipivaloyloxymethyl ester is valuable for research applications targeting STAT signaling pathways. -
STAT Inhibitor
Eupalinolide K is a selective STAT3 inhibitor derived from Eupatorium lindleyanum. This sesquiterpene lactone functions as a Michael reaction acceptor, demonstrating significant potential in modulating STAT3 signaling pathways. Its inhibitory activity makes Eupalinolide K useful in research related to cancer biology and inflammatory responses, providing insights into therapeutic strategies targeting the STAT3 pathway. -
STAT3 Inhibitor
STAT3-IN-7 is a potent inhibitor targeting Signal Transducer and Activator of Transcription 3 (STAT3). This aryl sulfonamido azetidine compound demonstrates significant anticancer properties, making it a valuable tool for research in cancer biology. It offers applications in studies aimed at elucidating the role of STAT3 signaling in tumor progression and therapeutic resistance. -
STAT3 Inhibitor
STAT3-IN-8 (compound H172) is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). It exhibits potent inhibitory activity against STAT3 signaling, which is often dysregulated in various cancers. This compound is valuable for cancer research, particularly in studies exploring the role of STAT3 in tumorigenesis and therapeutic interventions. -
STAT3 Inhibitor
HJC0149 is a selective inhibitor of signal transducer and activator of transcription 3 (STAT3), functioning by disrupting STAT3 signaling pathways. This compound exhibits potent biological activity, making it a valuable tool for research focused on cancer and inflammatory diseases where STAT3 plays a critical role in regulating cell proliferation and survival. Its efficacy positions HJC0149 as an essential reagent for investigating the therapeutic potential of STAT3 modulation in preclinical studies. -
STAT3 Inhibitor
STAT3-IN-29 is a selective inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). It demonstrates potent anti-proliferative effects on HaCaT cells with an IC50 value of 0.09 µM and has been shown to alleviate IMQ-induced psoriasis in mouse models. This compound is valuable for research aimed at understanding STAT3 signaling pathways and developing therapeutic strategies for psoriasis and other STAT3-related conditions. -
STAT3 Inhibitor
STAT3-IN-36 is a potent inhibitor of STAT3, with additional activity against LRPPRC and CDK1. This compound demonstrates significant anticancer effects, evidenced by its ability to inhibit HGC27 cells with an IC50 of 1.8 μM. STAT3-IN-36 serves as a valuable tool for research applications focused on cancer biology, particularly in elucidating the mechanistic roles of STAT3 and its associated pathways in tumor progression. -
STAT6 Inhibitor
STAT6-IN-11 is a selective inhibitor of the transcription factor STAT6, exhibiting an EC50 of 6 nM. It effectively reduces CCL17 secretion in peripheral human whole blood stimulated via the IL-13-IL-13 receptor/IL-4 receptor pathway, with an IC50 of 83 nM. This compound is valuable for research into dermatological and respiratory conditions, providing insights into the role of STAT6 in immune response and inflammation.
